Protocol Version 6.0  
Page 1 of 45  Feasibility Clinical Trial of the Cardio Flow FreedomFlow™ Orbital 
Atherectomy System to Treat Peripheral Artery Disease (FAST Trial) 
 
Protocol Number: 010-[ADDRESS_257915] Cardio Flow FreedomFlowTM Orbital Atherectomy System 
Regulatory Status Limited to Investigational Use Only 
Principal Investigator 
 [INVESTIGATOR_214665], MD 
 
Sponsor (mailing address for clinical study information) Cardio Flow, Inc. 
[ADDRESS_257916], 2nd Floor [LOCATION_011], MA [ZIP_CODE]
Duplex Ultrasound Core Laboratory [LOCATION_005] General Hospi[INVESTIGATOR_214666], 10th Floor 
[LOCATION_011], [LOCATION_005] [ZIP_CODE] 
 
 
This study will be conducted in compliance with Food and Drug Administration ( FDA) 
Regulations, [ADDRESS_257917] the study, and the presiding Institutional Review  Boards and governing regulatory agencies. The 
personnel provided with data from this study   are hereby [CONTACT_214686]. Release of these data to individuals othe r than those listed above requires the prior written 
permission of Cardio Flow, Inc. 
 
 
 
 
Protocol Version 6.0  
Page 2 of 45  Protocol Review and Approval Page  
 
 STUDY TITLE: Feasibility Clinical Trial of the Cardio Flow FreedomFlow™ Orbital 
Atherectomy System to Treat Periph eral Artery Disease (FAST Trial)  
PROTOCOL NUMBER: 010-031 
PROTOCOL VERSION: 6.0 PROTOCOL DATE: November 20, 2017   Investigator’s Statement: I agree to conduct this  clinical study in accordance with the design and 
specific provisions of this protocol; modificatio ns to the study or protocol are acceptable only 
with a mutually agreed upon protocol amendm ent. I agree to await IRB approval for the 
protocol and informed consent before initiati ng the study, to obtain informed consent from 
subjects prior to their enrollment in the study, to collect a nd record data as required by [CONTACT_214687], to prepare annual , final, and adverse event reports as required by 
[CONTACT_3181], and to maintain study docum entation for the period of time required. 
 
 
 
Investigator Name [CONTACT_214725]: _______________________________  Signature: _____________________________ Date of Signature: 
[CONTACT_214726]: 
 
  
 
Protocol Version 6.0  
Page 3 of 45  Protocol Synopsis  
Protocol Number and 
Version Number 010-031, Version 6.0 
Protocol Title Feasibility Clinical Trial of the Cardio Flow FreedomFlow™ Orbital Atherectomy 
System to Treat Peripheral Artery  Disease (FAST Trial) 
Investigational Product Cardio Flow FreedomFlow™ Orbital Atherectomy System 
 CM1001 – Control Module  
 H4001 –User Handle + Tubing Set  
Study Objective: To evaluate first-in-human safety an d effectiveness of the Cardio Flow 
FreedomFlow™ Orbital Atherectomy System for atherosclerotic plaque removal in de novo  native target lesions in the peripheral vasculature of the lower extremities. 
Study Design: Prospective, 2-cen ters, non-randomized single-arm study 
Enrollment Size and 
Number of Sites: Up to 10 subjects at up to 2 sites in the [LOCATION_002].   
Primary Safety 
Endpoint: 
 Freedom from a composite of new on-set major adverse events (MAE) at 30-day 
follow-up as adjudicated by [CONTACT_214688]. 
The components of the MAE are defined as: 
 Cardiovascular related death: All cardiovascular cause mortality. 
 Myocardial infarction (MI): Any newly diagnosed MI post procedure, defined 
as CK-MB ≥2X upper limit normal (ULN).  
 Clinically driven target lesi on revascularization (TLR): any repeat 
percutaneous or surgical intervention to  treat objectively do cumented symptoms 
of recurrent ischemia attributable to the treated lesion. 
 Clinically significant ta rget vessel dissection: NHLBI grade C or greater as 
confirmed by [CONTACT_89320]. 
 Clinically significant ta rget vessel perforation: NHLBI Type III as confirmed 
by [CONTACT_89320]. 
 Unplanned major target limb amputation: Amputation of the 
transmetatarsals or higher that was not previously planned as part of the overall 
treatment strategy. 
 Clinically relevant distal embolization: Emboli requiring surgical or medical 
intervention and/or the presence of symptoms. 
 Pseudoaneurysm: disruption of the arterial wall at the treatment site as 
confirmed by [CONTACT_89320] . 
 
Secondary Safety 
Endpoints:  Hemoglobin, hematocrit, and free hemoglobin (pre-and post-procedure and pre-
discharge) 
 Device and procedure related serious adverse events at 30 days and 6 months 
Primary Effectiveness:   Technical Success, defined as the ability of the Cardio Flow FreedomFlow™ 
Orbital Atherectomy System to achieve a residual diameter stenosis <50% post 
treatment without adjunctive therapy, as assessed by [CONTACT_214689]. 
Secondary Effectiveness:  Clinical Success, defined as the ability  of the Cardio Flow FreedomFlow™ 
 
Protocol Version 6.0  
Page 4 of 45  Orbital Atherectomy System to achieve a final residual diameter stenosis <50% 
with adjunctive therapy, determined by [CONTACT_214690]. 
 Procedure Success, defined as: 
o No procedure-related MAE 
o < 50% residual stenosis at target lesion 
o No device malfunction causing the procedure to be aborted 
 Percent of device run time less than 3 minutes cumulative total 
 Maximum balloon inflation pressure of the adjunctive plain balloon angioplasty 
and/or drug coated balloon angioplasty  
 Improvement of ABIs at 30 days and 6 months  
 Improvement of Rutherford Classification at 30 days and 6 months  
 Improvement of patient reported outcomes (PRO, VascuQoL questionnaire) at 30 
days and 6 months 
 Clinical driven target lesion revascularization (TLR), target vessel 
revascularization (TVR) at 30 days and 6 months (to be evaluated by 
[CONTACT_214691]) 
 Primary patency, primary assisted patency and secondary patency at 30 days and 
6 months. Doppler ultrasound examinations at 30 days and 6 months to confirm 
patency (to be evaluated by [CONTACT_214692]). The restenosis is defined as peak systolic velocity ratio (PSVR) of 2.5. 
Inclusion Criteria: 
   Subjects must meet all of the following criteria to be eligible for participation in the 
study: 
Inclusion Criteria 
1. Age ≥ [ADDRESS_257918] has a resting ankle-brachial index 
(ABI) ≤ 0.90, OR subjects with non- comp ressible arteries (ABI>1.1) must 
have a toe-brachial index (TBI) of ≤ 0.80. 
5. Clinical presentation of lifestyle limiting claudication or rest pain as 
characterized by [CONTACT_214693] 2, 3, 4, or 5. 
6. Subject has de novo target lesion(s) or lesion(s) treated by [CONTACT_214694] (PTA) only great er than 3 months prior with stenosis 
≥70% by [CONTACT_214695], superficial femoral, 
popliteal, anterior tibial, posterior tibial, or peroneal artery. Up to three lesions 
can be treated at the index procedure provided the cumulative total lesion 
length is ≤ 30 cm AND all lesions are in the same leg. 
7. Target reference vessel diameter (proximal to  and distal to target lesion) is [ADDRESS_257919] one patent vessel run-off to the ankle or foot at baseline.  
9. The target lesion(s) can be successfully crossed with a commercially available 
0.014” atherectomy guidewire without any complications during wiring 
 
Protocol Version 6.[ADDRESS_257920] signs a written Informed Consent form to participate in the study, prior 
to any study mandated determinations or procedure. 
Exclusion Criteria: Subject must be excluded from participatio n in this study if any of the following 
criteria are met:  
Exclusion Criteria  
1. Is female with childbearing potential no t taking adequate contraceptives or is 
currently breastfeeding.   
2. Target lesion is within a native graft or synthetic graft.  
3. Target lesion is an in-stent restenosis. 
4. Chronic total occlusion (CTO) with wire crossed near the advential junction. 
5. Subject has significant stenos is or occlusion of inflow tract (upstream disease) 
not successfully treated during the inde x procedure and prior to treatment of 
the target lesion.  
6. History of an endovascular procedure or open vascular surgery on the index 
limb within 30 days prior to the index procedure.  
7. Planned endovascular or surgical procedure within 30 days after the index 
procedure.  
8. Signs and symptoms of systemic infection (temperature of  ≥ 38.0° Celsius 
and/or WBC of ≥ 12,000 cells/µL) at the time of assessment;
     Note: If infection is adequately treated and controlled (temperature    < 
38.0° C and WBC < 12,000 cells/µL) patient may be enrolled .  
9. Unstable coronary artery disease or other comorbid condition(s) that, in the 
judgment of the physician precludes safe percutaneous intervention.  
10. Significant acute or chronic kidney diseas e with a creatinine level > 2.5mg/dL 
and/or requiring dialysis.  
11. Evidence or history of intracranial or gastrointestinal bleeding, intracranial 
aneurysm, myocardial infarction or stoke within 2 months of index procedure. 
12. Evidence or history of aneurysmal target vessel.  
13. Clinical/angiographic eviden ce of distal embolization. 
14. Known allergy to contrast agents or medications used to perform 
endovascular intervention that cannot be adequately pre-treated.   
15. Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is 
contraindicated.  
16. Heparin-induced thrombocytopenia (HIT) not able to use Bivalirudin.  
17. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia 
with platelet count less than 125,000/mm2, known coagulopathy, or INR > 
1.5.   
18. Thrombolytic therapy within 2 weeks of the index procedure. 
19. Intra-operative (intra-procedure) clinical or angiographic complication (other 
than non-flow limiting dissections) attributed to the use of a currently 
marketed device prior to introduction of the Cardio Flow atherectomy driveshaft.  
20. Has life expectancy < [ADDRESS_257921] is unwilling or unable to comply with the follow-up study 
requirements.  
22. Is currently participating in an investigational drug or another device study. 
 
Protocol Version 6.0  
Page 6 of 45  23. Has one or more stents in the treatment vessel.  
24. Lacking capacity to provide consent.  
Study Duration / Follow-
up Period:  Approximately [ADDRESS_257922] of care for 
atherectomy treatment of PAD.   
Analysis Population The primary analysis will be based on the intent-to-treat (ITT) population. 
 
 
 
  
 
Protocol Version 6.0  
Page 7 of 45  Table	of	Content	
1 BACKGROUND  AND RATIONALE  ....................................................................................................  11 
2 DEVICE DESCRIPTION  AND USE ......................................................................................................  12 
2.1 DEVICE DESCRIPTION  ...............................................................................................................................  12 
2.1.1 Control Module ............................................................................................................................... ... 13 
2.1.2 Tubing Set ............................................................................................................................... ........... 14 
2.1.3 User Handle ............................................................................................................................... ........ 15 
2.1.4 Driveshaft  Details ..............................................................................................................................  15 
2.2 INTENDED  USE ............................................................................................................................... ......... 16 
2.3 INDICATION  FOR USE ...............................................................................................................................  16 
3 STUDY PURPOSE  AND OBJECTIVE  ...................................................................................................  16 
4 STUDY DESIGN......................................................................................................................... ...... 16 
4.1 OVERVIEW ............................................................................................................................... .............. 16 
4.2 SAMPLE SIZE AND NUMBER OF CENTERS ......................................................................................................  17 
4.3 STUDY DURATION ............................................................................................................................... .... 17 
5 STUDY ENDPOINTS  ........................................................................................................................  17 
5.1 PRIMARY SAFETY ENDPOINTS ....................................................................................................................  17 
5.2 PRIMARY EFFECTIVENESS  ENDPOINT ...........................................................................................................  17 
5.3 SECONDARY  ENDPOINTS ...........................................................................................................................  18 
5.3.1 Secondary  Safety Endpoints  ...............................................................................................................  18 
5.3.2 Secondary  Effectiveness  Endpoints  ....................................................................................................  18 
6 STUDY PROCEDURE  .......................................................................................................................  18 
6.1 PATIENT ELIGIBILITY , PRE‐SCREENING  AND EXCLUSIONS ..................................................................................  18 
6.1.1 Inclusion Criteria ............................................................................................................................... . 19 
6.1.2 Exclusion Criteria ...............................................................................................................................  19 
6.2 PRE‐SCREENING  AND WRITTEN INFORMED  CONSENT .....................................................................................  21 
6.3 ENROLLMENT  ............................................................................................................................... .......... 21 
6.4 BASELINE EVALUATION  (WITHIN 30 DAYS OF INDEX PROCEDURE ) ....................................................................  21 
6.5 INDEX PROCEDURE ............................................................................................................................... ... 22 
6.5.1 Angiography  ............................................................................................................................... ....... 22 
6.5.2 Non‐Target Vessel/Lesion  Intervention  .............................................................................................  22 
 
Protocol Version 6.0  
Page 8 of 45  6.5.3 Cardio Flow FreedomFlow™  Orbital Atherectomy  Procedure  ............................................................  [ADDRESS_257923] PROCEDURE  TO DISCHARGE ...............................................................................................................  25 
6.7 30 DAYS FOLLOW‐UP (± 7 DAYS) ...............................................................................................................  26 
6.8 6 MONTHS FOLLOW‐UP (± 14 DAYS) .........................................................................................................  26 
6.9 UNPLANNED  FOLLOW‐UP .........................................................................................................................  [ADDRESS_257924] EARLY DISCONTINUATION  / WITHDRAWAL  AND REPLACEMENT  OF SUBJECTS ..........................................  [ADDRESS_257925] TO FOLLOW‐UP ...............................................................................................................................  27 
7 BENEFIT / RISK ANALYSIS  ...............................................................................................................  [ADDRESS_257926] IDENTIFICATION  ..........................................................................................................................  29 
9.2 CENTRAL DATABASE ............................................................................................................................... . 29 
9.3 SOURCE DOCUMENTS  ..............................................................................................................................  30 
9.4 DATA COLLECTION ............................................................................................................................... .... 30 
9.5 DATA PROCESSING ............................................................................................................................... ... 30 
9.6 STUDY REPORT ............................................................................................................................... ........ 30 
10 STUDY ADMINISTRATION  ..............................................................................................................  30 
10.1 MONITORING  ............................................................................................................................... .......... 30 
10.1.1 Monitoring  Procedures  ......................................................................................................................  30 
10.1.2 Monitoring  Visit ............................................................................................................................... .. 31 
10.1.3 Study Closure ............................................................................................................................... ...... 32 
10.2 DEVICE ACCOUNTABILITY  ..........................................................................................................................  32 
11 DEFINITION  OF ADVERSE  EVENT(S)  ................................................................................................  [ADDRESS_257927] ....................................................................................................  34 
11.4 ADVERSE EVENT REPORTING .....................................................................................................................  34 
11.5 ADVERSE EVENT ASSESSMENT  ...................................................................................................................  35 
 
Protocol Version 6.0  
Page 9 of 45  11.5.1 Initial Assessment  ..............................................................................................................................  35 
11.5.2 Assessment  of Severity ......................................................................................................................  35 
11.5.3 Device Relatedness  ............................................................................................................................  36 
11.6 DEVICE DEFICIENCY  OR MALFUNCTION  ........................................................................................................  36 
11.7 REPORTING  OF DEATH ..............................................................................................................................  37 
12 STUDY ADMINISTRATIV  OVERSIGHT  ..............................................................................................  37 
12.1 CORE LABORATORY  ............................................................................................................................... ... 37 
12.2 CLINICAL ADVERSE EVENT ADJUDICATION  ....................................................................................................  37 
12.3 IRB APPROVAL ............................................................................................................................... ........ 38 
12.4 INFORMED  CONSENT ...............................................................................................................................  38 
12.5 RECORDS ............................................................................................................................... ................  39 
12.6 REPORTS ............................................................................................................................... ................  39 
12.7 INVESTIGATOR  RESPONSIBILITIES  ................................................................................................................  40 
12.8 SPONSOR RESPONSIBILITIES  .......................................................................................................................  41 
12.9 PROTOCOL  DEVIATIONS  / VIOLATIONS  AND MEDICAL EMERGENCIES  .................................................................  42 
12.10 PRE‐STUDY DOCUMENTATION  REQUIREMENTS  .............................................................................................  [ADDRESS_257928] of Tables 
Table 6-1: Schedule of Events ................................................................................................. .................. 26  
Table 12-1: Reports Required fro m Investigators to Sponsor ................................................................... [ADDRESS_257929] of Figures 
Figure 2-1: FreedomFlow™ Orbital Atherectomy System ....................................................................... 13  
Figure 2-2: Control Module..................................................................................................... .................. 14  
Figure 2-3: Tubing Set ........................................................................................................ ...................... 14  
Figure 2-4: User Handle ....................................................................................................... ..................... 15  
Figure 2-5: Driveshaft Tip .................................................................................................... ..................... 16  
 
  
 
Protocol Version 6.0  
Page 11 of 45  1 BACKGROUND AND RATIONALE 
Atherosclerosis causes symptomatic disease primar ily in the coronary arteries, the peripheral 
arteries of the lower extremities, and the extra-cranial carotid arteries.1 Of the three, peripheral 
artery disease (PAD) is probably the most un der-diagnosed and least aggressively managed, 
despi[INVESTIGATOR_214667] (CVD) and de ath.  PAD is chronic 
occlusive artery disease of the lower extremities and a strong surrogate marker for atherosclerosis in the heart, kidneys, and brain.
1,3,4,5 PAD is associated with a 60% incidence of coronary or 
cerebrovascular disease.6 About 90% of patients with sympto matic PAD have coronary artery 
disease (CAD) as well.[ADDRESS_257930] devastating e ffects on quality of life and survival, 
with mortality around 30% in 5 years, 50% in 10 years and 75% in 15 years.8   Overall, CVD 
causes death in 75% of PAD patients. 
Most common among elderly people, diabetics, a nd smokers, PAD afflicts an estimated 8-12 
million people in the [LOCATION_002] alone. Its preval ence is likely to increase greatly in the next 
several decades as the risk factors of di abetes, smoking, hypertension, dyslipi[INVESTIGATOR_214668]. 
Classic symptoms of PAD include intermittent cla udication (IC), defined as leg muscle pain or 
weakness that occurs during walk ing and subsides with rest.[ADDRESS_257931] pain in the toes or foot indicates 
that arterial blood flow cannot meet the needs of  resting metabolism. The resulting critical limb 
ischemia (CLI) can progress to ulceration or ga ngrene in the toes, ankl e, heel, or leg, often 
necessitating amputation.[ADDRESS_257932] poor physical function.9 Detecting 
asymptomatic PAD requires measuring and calcul ating the ankle/brachial index (ABI), obtained 
by [CONTACT_214696] e by [CONTACT_214697].10 In a healthy person, the ABI is 0.9 to 1.2. An ABI under 0.9 is 95% sensitive and 99% 
specific for the diagnosis of PAD. The lower the AB I level, the more serious is the ischemia. An 
ABI of 0.5 is associated with a 63% five-year survival rate, and ABIs between 0.[ADDRESS_257933] false normal ABIs. To diagnose such patients, vascular 
laboratories can measure a toe/brach ial index or do other noninvasive  testing. Physicians can also 
use an exercise ABI measurement to assess IC patients with normal ABI scores.12, 13 
The overall goals of PAD treatment are to main tain or improve function, reduce or eliminate 
ischemic symptoms and prevent disease progression.2 Current treatments include exercise, 
medical  treatment  to  lower  cholesterol  and  blood  pressure,  and  su rgery  or percutaneous 
interventions to restore blood flow in patients wi th intermittent claudica tion (IC) or critical limb 
ischemia (CLI).14 Invasive treatments include by[CONTACT_214698], percutaneous transluminal 
angioplasty (PTA)15, percutaneous atherectomy (directional or rotational)16, endarterectomy, 
excimer laser combined with PTA17 and stenting (drug-elu ting stents) of the oc cluded or stenosed 
vessel. Therapeutic angiogenesis, which uses  angiogenic growth fa ctors or bone marrow 
mononuclear cell therapy to stimulate growth of new blood vessels18, and subintimal 
 
Protocol Version 6.[ADDRESS_257934] better results than in the 
femoropopliteal arteries, and in turn, results in th e femoropopliteal arteries tend to be better than 
those in the smaller lower-leg arteries. 
Atherectomy is a minimally i nvasive endovascular technique for removing atherosclerotic 
plaque from blood vessels within  the body. There are three main types of atherectomy devices: 
directional, laser, and rotationa l, which includes a s ubset known as orbita l. The current U.S. 
Food and Drug Administration (FDA)  cleared devices for periphe ral atherectomy include the 
SilverHawk™, TurboElite™, Rotoblator™, Diamondback™, JetStream™, Phoenix™, and 
Pantheris™. Cardio Flow, Inc. has pi[INVESTIGATOR_214669] a dvances in orbital atherectomy technology for the 
intravascular treatment of PAD using the Cardio Flow FreedomFlowTM Orbital Atherectomy 
System. 
The Cardio Flow FreedomFlowTM Orbital Atherectomy System is intended to remove fibrous and 
calcified stenotic plaque using diamond-coated eccentric spheres a ttached to a driveshaft in a 
spi[INVESTIGATOR_214670].  The device intended to  operate over a commercially available 0.014’ 
atherectomy guidewire to treat vessels from 2mm to  5mm in diameter. No driveshaft lubricant is 
required for use with the Cardio Flow FreedomFlowTM Orbital Atherectomy System.   
One GLP-like porcine studies (2 pi[INVESTIGATOR_14107]) were conduc ted to assess safety and device performance in 
normal peripheral arteries a range of vessel si zes.  Devices were operated according to the 
Instruction for Use.  Animals were survived for three days post-treatment  and the treated vessels 
were harvested and histopathol ogical evaluation performed. 
One human cadaver study (3 limbs) was also conduc ted according to the Instruction for Use.  The 
limb studies were utilized to obtain particulat e from the atherectomy procedure for a size 
distribution analysis and to observe device operation in occluded arteries.  
2 DEVICE DESCRIPTION AND USE 
2.1 Device Description 
The FreedomFlow™ Orbital Atherectomy System c onsists of a Control Module, Tubing Set, and 
User Handle. It is designed to remove atheroscle rotic plaque from peripheral arteries by [CONTACT_214699]-coated spheres mounted eccentrically on a coiled driveshaft. The Control Module is 
reusable capi[INVESTIGATOR_140325]. The Tubing Set and Us er Handle are single-use sterile devices. The 
User Handle is used to activate rotation and a dvance the driveshaft on a commercially available 
0.014-inch bare-metal atherectom y guidewire. The guidewire a nd introducer sheath are not 
included with the system. The Tubing Set and User Handle are the only parts of the system applied 
to the patient. 
 
 
Protocol Version 6.0  
Page 13 of 45   
          
Figure 2-1: FreedomFlow™ Orbital Atherectomy System 
 
2.1.[ADDRESS_257935] 5-wheel IV pole. 
 
Control 
Module 
Tubing Set 
User 
 
Protocol Version 6.0  
Page 14 of 45   
 
Figure 2-2: Control Module  
2.1.2 Tubing Set 
The Tubing Set is a single-use component that is packaged with the User Handle. The Tubing Set 
is supplied sterile (via Ethylene Oxide gas). The set delivers saline and pressurized gas from the 
Control Module to the User Handle. A cable and se nsor relay orbital speed  back to the Control 
Module.  
 
 
Figure 2-3: Tubing Set  
 

 
Protocol Version 6.0  
Page 15 of 45  2.1.3 User Handle 
The User Handle is a single-use component that provides control over rotation and translational 
movement of the integrated driveshaft. The User  Handle is supplied sterile (via Ethylene Oxide 
gas). A spring-loaded button on the User Handle is depressed to act ivate the pneumatic driveshaft 
and released to stop rotation. The turbine carriage  of the User Handle has [ADDRESS_257936] the driveshaft’s di amond-coated distal tip and eccentrically mounted 
diamond-coated spheres independently of the cat heter tubing. The User Handle guidewire clamp 
prevents guidewire movement during use.  User Handle H4001 will be evaluated in this clinical 
trial and can be used to treat a range of vessel sizes. Refer to Instructions for Use for guidance on appropriate vessel sizes that can be  treated with User Handle H4001. 
 
Figure 2-4: User Handle 
2.1.[ADDRESS_257937] centrifugal direction dur ing rotation. The diamond-coated distal tip is designed to add 
stability and may ease transition into a tight stenotic lesion. 
   

 
Protocol Version 6.0  
Page 16 of 45   
Figure 2-5: Driveshaft Tip 
The Cardio Flow Orbital Atherectomy User Handle and Tubing Set are ster ile, disposable devices 
that are intended for use during a single patient procedure and are used w ith the Control Module, 
which is a non-sterile, reusable un it that controls system operation. 
2.2 Intended Use 
The FreedomFlow™ Orbital Atherectomy System is  a minimally invasive, catheter-based system 
designed for improving luminal diameter in patients with PAD. 
2.3 Indication For Use 
The FreedomFlow™ Orbital Atherectomy System is applied as therapy to remove atherosclerotic 
plaque within peripheral arterial vessels. The therapy is intended for patients who are acceptable 
candidates for percutaneous transluminal atherectomy. 
[ADDRESS_257938]-in-human safety and effectiveness of 
the FreedomFlow™ Orbital Atherectomy System for atherosclerotic plaque removal in de novo  
target lesions in the peripheral vasculature of the lower extremities. 
[ADDRESS_257939] in human (FIH) prospective, two-center, non-randomized single-arm study designed 
to evaluate the safety and effectiveness of the FreedomFlow™ Orbital Atherectomy System in 
subjects diagnosed with pe ripheral arterial disease of  the lower extremities.  

 
Protocol Version 6.[ADDRESS_257940]-procedure follow-up. 
5 STUDY ENDPOINTS 
5.1 Primary Safety Endpoints 
The primary safety endpoint is freedom from a composite of new on-set major adverse events 
(MAE) through 30-day follow-up as adjudicated by [CONTACT_214700]. 
The components of the MAE are defined as: 
 Cardiovascular related death: All cardiovascular cause mortality. 
 Myocardial infarction (MI): Any newly diagnosed MI post procedure, defined as 
CK-MB ≥2X upper limit normal (ULN).     
 Clinically driven target le sion revascularization (TLR): any repeat percutaneous 
or surgical intervention to treat object ively documented symptoms of recurrent 
ischemia attributable to the treated lesion. 
 Clinically significant ta rget vessel dissection: NHLBI grade C or greater as 
confirmed by [CONTACT_89320]. 
 Clinically significant targ et vessel perforation: NHLBI Type III as confirmed by 
[CONTACT_89320]. 
 Unplanned major target limb amputation: Amputation of the transmetatarsals or 
higher that was not previously planned as  part of the overall treatment strategy. 
 Clinically relevant distal embolization: Emboli requiring surgical or medical 
intervention and/or the presence of symptoms. 
 Pseudoaneurysm: disruption of the arterial wall at the treatment site as confirmed 
by [CONTACT_89320].  
5.2 Primary Effectiveness Endpoint 
The primary effectiveness endpoint is technical success. The technical success is defined as the 
ability of the FreedomFlow™ Orbital Atherectomy Sy stem to achieve a residual diameter stenosis 
<50% immediately post treatment without adj unctive balloon inflation, as assessed by [CONTACT_214701]. 
 
 
Protocol Version 6.0  
Page 18 of 45  5.3 Secondary Endpoints 
5.3.1 Secondary Safety Endpoints 
 Hemoglobin, hematocrit, and free hemogl obin (pre-procedure, immediately post-
procedure, and at discharge) wi ll be measured and reported. 
 All device and procedure related serious adverse events at [ADDRESS_257941] procedure. 
5.3.2 Secondary Effectiveness Endpoints 
 Clinical Success, defined as the abilit y of the FreedomFlow™ Orbital Atherectomy 
System to achieve a final residual diam eter stenosis <50% with or without 
adjunctive low pressure balloon therapy, determined by [CONTACT_214702]. 
 Procedure Success, defined as: 
o No procedure-related MAE 
o < 50% residual stenosis at target lesion 
o No device malfunction causing th e procedure to be aborted 
 Percent of device run time less than 3 minutes cumulative total 
 Maximum balloon inflation pressure with  adjunctive plain balloon angioplasty 
and/or drug coated balloon angioplasty  
 Improvement of ABIs at 30 days and 6 months 
 Improvement of Rutherford Classifi cation at 30 days and 6 months.  
 Improvement of patient reported outcomes  (PRO, VascuQoL questionnaire) at 30 
days and 6 months 
 Clinical driven target lesion revasculariza tion (TLR), target vessel revascularization 
(TVR) at 30 days and 6 months (diagnosis of TLR and TVR to be verified by [CONTACT_214703]) 
 Primary patency, primary assisted patency and secondary patency at [ADDRESS_257942] ex ultrasound and evaluated by a Duplex 
Ultrasound core laboratory). The reste nosis is defined as PSVR of 2.5 
6 STUDY PROCEDURE 
6.1 Patient Eligibility, Pre-scr eening and Exclusions 
All patients scheduled for a percutaneous en dovascular intervention for PAD in the lower 
extremity will be screened for study eligibility. A Screening/Enrollment Log will be provided to 
the study sites, in order to maintain a cu mulative tracking of all screened patients. 
Subjects must meet all inclusion/exclusion criteri a for enrollment in the clinical study. Reasons 
for screening failure(s) will be documented. 
 
Protocol Version 6.[ADDRESS_257943] meet ALL of the following criteria  to be eligible for participation in the 
study: 
1. Age ≥ [ADDRESS_257944] has a resting ankle-
brachial index (ABI) ≤ 0.90, OR subjects with non- compressible 
arteries (ABI>1.1) must have a toe-brachial index (TBI) of ≤ 0.80. 
5. Clinical presentation of lifestyle li miting claudication or rest pain as 
characterized by [CONTACT_214704] 2, 3, 4, or 5. 
6. Subject has de novo target lesion(s) or lesion(s) treated by [CONTACT_214694] (PTA) only greater than 3 months prior with 
stenosis ≥70% by [CONTACT_214695], superficial 
femoral, popliteal, anterior tibial, post erior tibial, or pe roneal artery. Up 
to three lesions can be treated at  the index procedure provided the 
cumulative total lesion length is ≤ 30 cm AND all lesions are in the 
same leg. 
7. Target reference vessel diameter (proxi mal and distal to target lesion) is 
[ADDRESS_257945] one patent vessel run-off to  the ankle or foot at baseline.  
9. The target lesion(s) can be successfully crossed with a commercially 
available 0.014” atherectomy guide wire without any complications 
during wiring procedure. 
10. Subject signs a written Informed Consent form to participate in the 
study, prior to any study mandated determinations or procedure. 
6.1.[ADDRESS_257946] be EXCLUDED from participa tion in this study if ANY of the following 
criteria are met: 
1. Is female with childbearing potential not taking adequate 
contraceptives or is currently breastfeeding. 
2. Target lesion is within a native graft or synthetic graft. 
3. Target lesion is an in-stent restenosis. 
4. Chronic total occlusion (CTO) with wire crossed near the advential 
junction. 
5. Subject has significant stenosis or oc clusion of inflow tract (upstream 
 
Protocol Version 6.0  
Page 20 of 45  disease) not successfully treated dur ing the index procedure and prior 
to treatment of the target lesion. 
6. History of an endovascular procedur e or open vascular surgery on the 
index limb within 30 days pr ior to the index procedure. 
7. Planned endovascular or surgical procedure within 30 days after the 
index procedure. 
8. Signs and symptoms of systemic  infection (temperature of  ≥ 38.0° 
Celsius and/or WBC of ≥ 12,000 cells/µL) at the time of assessment; 
     Note: If infection is adequately trea ted and controlled (temperature    
< 38.0° C and WBC < 12,000 cells/µL) patient may be enrolled . 
9. Unstable coronary artery disease or other comorbid condition(s) that, in 
the judgment of the physician preclude s safe percutaneous intervention. 
10. Significant acute or chronic kidney disease with a creatinine level > 
2.5mg/dL and/or requiring dialysis. 
11. Evidence or history of intracranial or gastro intestinal bleeding, 
intracranial aneurysm, myocardial in farction or stoke within 2 months 
of index procedure. 
12. Evidence or history of an eurysmal target vessel. 
13. Clinical/angiographic eviden ce of distal embolization. 
14. Known allergy to contrast agents or medications used to perform 
endovascular intervention that ca nnot be adequately pre-treated. 
15. Subjects in whom anti-platelet, antico agulant, or thrombolytic therapy 
is contraindicated. 
16. Heparin-induced thrombocytopenia (HIT) not able to use Bivalirudin. 
17. Uncorrectable bleeding diathe sis, platelet dysfunction, 
thrombocytopenia with platelet  count less than  125,000/mm2, known 
coagulopathy, or INR > 1.5. 
18. Thrombolytic therapy within 2 weeks of the index procedure. 
19. Intra-operative (intra-procedure) clin ical or angiographic complication 
(other than non-flow limiting dissec tions) attributed to the use of a 
currently marketed device prior to  introduction of the Cardio Flow 
atherectomy driveshaft. 
20. Has life expectancy < [ADDRESS_257947] is unwilling or unable to comply with the follow-up study 
requirements.  
22. Is currently participating in an i nvestigational drug or device study.  
23. Has one or more stents in the treatment vessel. 
24. Lacking capacity to provide consent. 
 
Protocol Version 6.0  
Page 21 of 45  6.2 Pre-screening and Written Informed Consent 
The site may pre-screen poten tial subjects by [CONTACT_214705] l records to identify the study 
population.  Once identified these subjects are appr oached for the study and consented.  The site 
may not initiate any study specific (non-standard of care) procedures without first obtaining 
informed consent 
Subjects who pass the initial pre-screening will be asked to sign the study specific IRB approved 
Informed Consent.  A member of the research t eam will approach the subj ect to obtain informed 
consent. The background of the proposed study, the procedure, the follow-up schedule and all 
potential benefits and risks will be carefully explained to the subject prior to obtaining the 
potential subject’s informed consent. A subject is  considered “Enrolled” after signing the study 
specific Informed Consent and if he/she meet s all inclusion and exclusion criteria.   
Informed consent will be obtained prior to any study specific screen ing/baseline tests are 
performed. This does not include any procedures or tests that are obtained vi a the standard of care 
related to the subjec t’s non-study related care, prior to  undergoing the in dex procedure. 
6.3 Enrollment 
Only subjects who meet the inclusion/exclusion cr iteria, and provide consent will be eligible to 
receive the treatment and participate in the study.  A subject will be considered officially enrolled 
only if the subject has signed informed consent, meets all the inclusion and none of the exclusion 
criteria and is treated with the device. 
6.4 Baseline Evaluation (Within 30 Days of Index Procedure) 
Subjects that meet the pre-screening eligibility criteria and signed informed consent will have the 
following collected.  These evaluations can occur a nytime within 30 days of the procedure to the 
day of treatment.  Only one angiogram is required. 
 Demographic Information: ra ce, age, weight, height 
 Medical History / Current Status 
 Physical Exam and Vital Signs 
 Angiogram (recorded an d sent to sponsor) 
 Duplex Ultrasound (if available, recorded and sent to sponsor) 
 Rutherford Classification 
 Laboratory Assessments: 
o CBC, creatinine, and potassium (on day of procedure) 
o INR & PT if subject is on chronic wa rfarin therapy (on day of procedure) 
o Urine pregnancy test if female of ch ild-bearing potential (within 7 days of 
procedure) 
o Hemoglobin, hematocrit, and free hem oglobin (pre-procedure, immediately 
post-procedure, and at discharge). 
 
Protocol Version 6.0  
Page 22 of 45   VascuQoL Questionnaire 
 Ankle Brachial Index (ABI) 
 Concomitant Medications 
6.[ADDRESS_257948] their scheduled index procedure 
performed in accordance with physician/i nvestigational site standard practices. 
6.5.[ADDRESS_257949] is considered as “enrolled” after the 
subject meets all angiographic criteria an d a bare-metal atherectomy 0.014” guidewire 
successfully crosses the target lesion via the true vessel lumen.  
Angiography will be performed throughout the pr ocedure to document the treatment outcomes 
and sent to the sponsor.  At a minimum, angiographic images at the following timepoint should 
be taken.   
 Baseline angiography to determ ine subject’s eligibility. 
 Post any lesions that are pre-dilated by [CONTACT_214706].  
 After the Cardio Flow FreedomFlow™ orbi tal atherectomy treatment session(s). 
 Post any adjunctive interventions, e.g. balloon angioplasty an d/or stenting, to 
optimize the outcome or bailout the procedure due to vascular complications. 
 Final angiography prior to th e end of the procedure. 
Up to 3 target lesions are allowed based on the a ngiographic criteria by [CONTACT_3181]. If 2 or 3 
target lesions are selected, the lesion will be numbered based on the anatomic order, i.e. common femoral artery, proximal, middle or distal segmen t of superficial femoral artery, P1, P2 or P3 
segment of popliteal artery, anterior tibial artery, posterior tibial artery, and peroneal artery, regardless of the treatment order.  
6.5.2 Non-Target Vessel/Lesion Intervention 
Non-target vessels/lesions can be staged and tr eated with any commercially available devices 
greater than [ADDRESS_257950] the index pro cedure. If a non-target lesion(s) that locates at 
the iliac artery or at the femoral artery with a vessel size greater than 5 mm in diameter in the 
target limb and requires intervention during the i ndex procedure, the lesion(s) MUST be treated 
with commercially available devices prior to th e Cardioflow orbital athe rectomy procedure. The 
CardioFlow orbital atherectomy procedure can be performed ONLY if th ere are no angiographic 
complications at the non-target vessel/lesion si te and downstream vascul atures and no clinical 
 
Protocol Version 6.0  
Page 23 of 45  adverse event. If any angiographic complicati on at the non-target ve ssel/lesion site and 
downstream vasculatures or clinic al adverse event occurred, the subject MUST not proceed to the 
CardioFlow orbital atherectomy procedure. The s ubject will be considered as an angiographic 
screening failure.     
6.5.3 Cardio Flow FreedomFlow™ Or bital Atherectomy Procedure 
Subjects that meet the final angiographic el igibility criteria will have the atherectomy 
procedure performed according to the Cardio Flow FreedomFlowTM Orbital Atherectomy 
System Instructions for Use (IFU). 
Performing the Atherectomy Procedure 
Interventionalist will place commercially available 0.014-inch bare-metal atherectomy 
guidewire through appropriate size introducer sheath based on User Handle model. See 
IFU provided with the device for details.  If this summary differs from the IFU, follow 
the IFU 
Caution:  If the physician suspects the guidew ire is placed sub-intimally, the 
atherectomy procedure must be abor ted and alternative care performed . 
1. Once the system is prepped with sterile saline, the distal tip of the User Handle 
driveshaft can be inserted onto the proxima l end of the placed guidewire. Ensure that 
the guidewire clamp at the back of the User Handle is rotated to the open position to allow the guidewire to exit the User Handle. 
2. While utilizing imaging technology (fluoroscopy and/or ultrasound), the 
physician advances the User Handle drives haft over the guid ewire through the 
introducer sheath and into th e patient’s vasculature. Continue advancement of the 
driveshaft and spheres until positioned proximal to the target lesion. 
Caution: Verify that the guidewire dist al tip is advanced as far distally in 
patient vasculature as feasible to ensure User Handle driveshaft does not 
contact [CONTACT_214707]. 
3. Once the driveshaft is in the desired location, rotate guidewire clamp clockwise 
and verify that the guidewire can no longer fr eely move. Verify that no saline solution 
is leaking from the guidewire clamp. 
4. Select the appropriate speed for th e vessel size on the touch screen.  
Caution: A tight lesion stenosis may require a lower speed, prior to 
sequential higher speed treatments. Start rotation proximal to a tight lesion 
stenosis. 
5. Fully depress the blue activation button to  initiate rotation and maintain selected 
speed. 
 
Protocol Version 6.[ADDRESS_257951] through the target lesion. 
Warning: Performing atherectomy in th e presence of severe arterial spasm 
can result in vessel dissection or perfor ation. If severe spasm is observed 
during treatment with the Freed omFlow™ Atherectomy System, 
immediately stop driveshaft rotation. If  no dissections or perforations are 
detected, resume treatment only aft er the vessel spasm has spontaneously 
resolved or is treated pharmacologica lly. Prophylactic and epi[INVESTIGATOR_214671]-
spasm treatment may be administe red as described in section 6.5.4 
Procedure Medications in this protocol. 
Caution: Do not leave the spheres of th e driveshaft in one location for more 
than [ADDRESS_257952] is recommended. 
Caution: Frequent imaging evaluation, such as contrast fluoroscopy and/or 
ultrasound, should be utilized throughout the treatment procedure to 
evaluate lesion removal progress and id entify potential dissections.  The 
investigational treatment should be disc ontinued if a dissection is detected 
7. To stop driveshaft rotation, re lease blue activ ation button. 
Caution: If rotation does not cease wi th release of blue activation button, 
disconnect the Tubing Set from the User Handle.  
8. To move the driveshaft to a different target lesion, rotate  the guidewire clamp 
counterclockwise to allow th e driveshaft to move independently of guidewire. 
9. Rotate guidewire clamp clockwise to lock guidewire before activating the 
driveshaft again. 
 
Removal of the User Handle and Driveshaft 
1. Release blue activation button to stop ro tation and retract driveshaft proximal to 
the lesion using the turbine carriage. 
2. Rotate guidewire clamp counterclockwise so that User Handle and driveshaft can 
move independently of guidewire. 
3. Carefully remove the driveshaft from  the guidewire through introducer sheath. 
4. Turn off peristaltic pump by [CONTACT_53737][INVESTIGATOR_214672] e OFF icon on the Control Module touch 
screen. 
5. Dispose of User Handle and Tubing Set according to standard hospi[INVESTIGATOR_13707]. 
 
Protocol Version 6.[ADDRESS_257953] be paused. If 
the peristaltic pump door is opened during a procedure, pneumatic power to the User 
Handle will cease immediately. 
1. Remove the User Handle and driveshaft from patient (see instructions above). 
2. Turn off peristaltic pump by [CONTACT_53737][INVESTIGATOR_214672] e OFF icon on the Control Module touch 
screen. 
3. Disconnect current saline infusion bag fr om IV spi[INVESTIGATOR_214673] t the introduction of air. 
4. Without touching the sterile IV spi[INVESTIGATOR_214674], insert a new saline infusion bag onto 
the IV spi[INVESTIGATOR_214675]. 
5. Repeat a complete flush cycle of  the User Handle and driveshaft.  
6.5.4 Procedure Medications  
Warning: Performing atherectomy in the presen ce of severe arterial spasm can result in 
vessel dissection or perforation. If severe sp asm is observed during treatment with the 
FreedomFlow™ Atherectomy System, immedi ately stop driveshaft rotation. 
Anti-coagulation medication and loading dose of an ti-platelet medications will be given prior to 
the atherectomy procedure per investigationa l site atherectomy standard procedure. 
Antispasmodic medications such as nitroglyceri ne (200 µg intra-arteri al (IA) bolus; up to [ADDRESS_257954]) or papaverine (300 µg IA bolus) may be admini stered. To avoid frequent IA 
bolus injections, the following solution (500 ml normal saline with 3000 µg heparin, 3000 µg  
nitroglycerin and 2.5 mg Cardizem) can be infused intra-arterially at a rate of 6 mL/min. All 
medications administered for this study should be  recorded in the subject ’s medical record.   
During the procedure, any device malfuncti on and device/procedure related adverse 
events, including anaphylaxis to medications  or device components will be monitored 
and recorded.  
6.[ADDRESS_257955]: 
 Physical Exam and Vital Signs 
 Hemoglobin, hematocrit, and free hemoglobin  
 Adverse Events assessment  
 
Protocol Version 6.0  
Page 26 of 45  6.7 30 Days Follow-up (± 7 Days) 
Subjects will return for a follow-up visit at 30 days and the following assessments will be 
performed: 
 Physical Exam and Vital Signs 
 Rutherford Classification 
 ABI 
 Duplex Ultrasound of treated lesion per Ultra Sound Core Lab protocol 
 Angiogram – performed only if  clinical symptoms requi ring intervention during 
follow-up for TVR or TLR 
 VascuQoL Questionnaire 
 Adverse Events assessment 
6.8 6 Months Follow-up (± 14 Days) 
Subjects will return for a follow-up visit at 6 months and the following assessments will be 
performed: 
 Physical Exam and Vital Signs 
 Rutherford Classification 
 ABI 
 Duplex Ultrasound of treated lesion per Ultra Sound Core Lab protocol 
 Angiogram – performed only if  clinical symptoms requi ring intervention during 
follow-up for TVR or TLR 
 VascuQoL Questionnaire 
 Adverse Events assessment 
Table 6-1: Schedule of Events 
 
Assessment Screening 
/ 
Baseline/Pre-
procedure  
Procedure  
Discharge 30 Days 
(±7 days) 6 months 
(±14 days) 
Informed Consent X     
Medical History X     
Physical Exam X  X X X 
Laboratory Assessments X X    
 
Protocol Version 6.[ADDRESS_257956] Classification X   X X 
ABI X   X X 
VascuQoL Questionnaire X   X X 
Hemoglobin, hematocrit, and free hemoglobin  X X X   
Angiogram X X  Xa Xa 
Duplex Ultrasound Xb   X X 
Medications X  X X X 
Adverse Events X X X X X 
aAngiograms will be performed at the follow-up visits  for verification of restenosis of the treated 
lesion/vessel site(s) only if the subject has clinical symptoms requiring intervention. 
b if available 
 
6.9 Unplanned Follow-up 
Subjects returning for unscheduled visits compla ining of new signs and/or symptoms will be 
documented as an unplanned follow-up and, at the investigators’ discre tion perform diagnostic 
evaluations.  The reason should be reported as an adverse event if applicable.  
6.[ADDRESS_257957] Early Discontinuation / Withdrawal and Replacement 
of Subjects 
All subjects are informed of their right to withdraw from the clinical study at any time. 
Additionally, the investigat or may prematurely discontinue any s ubject’s participa tion in the study 
if the investigator feels that the subject can no longer fully comply with the requirements of the 
study or if any of the study pro cedures are deemed potentially harmful to the subject. However, 
it is anticipated that such withdrawals will be in frequent to ensure the integrity of the study. The 
reason for early discontinuation will be documen ted in the source documents and case report 
forms. 
6.[ADDRESS_257958]’s last known address. 
7 BENEFIT / RISK ANALYSIS 
7.[ADDRESS_257959] benefits of  participating in this 
study. Information gathered from this  study will help confirm the sa fety and efficacy of the device 
in treating de novo, severely ca lcified periphera l lesions.   
7.2 Risks 
The risks of the investigational procedure to su bjects is similar to that of other Atherectomy 
procedures.   
Possible risks associated with the Cardio Flow  FreedomFlow™ Orbital Atherectomy System that 
may occur and/or require interventi on include, but are not limited to: 
 Allergic reaction to medicat ion/media/device components 
 Amputation 
 Anemia 
 Aneurysm 
 Bleeding complications whic h may require transfusion 
 Cerebrovascular accident (CVA) 
 Death 
 Distal embolization 
 Device embolization 
 Entry site complications  including hematoma 
 Hemolysis 
 Hypotension/hypertension 
 Infection 
 Myocardial infarction 
 Pain 
 Pseudoaneurysm 
 Restenosis of treated segment th at may require revascularization 
 Renal insufficiency/failure 
 Slow flow or no reflow phenomenon 
 Dissection 
 Perforation 
 Thrombus 
 
Protocol Version 6.0  
Page 29 of 45   Vessel closure, abrupt 
 Vessel injury, including dissec tion and perforation that may require surgical repair 
 Vessel spasm 
 Vessel occlusion 
7.[ADDRESS_257960] design, 
testing, and through careful labeli ng and instructions for use. 
8 STATISTICS 
This study is a one or two cente r, prospective, non-randomized si ngle-arm Early Feasibility Study. 
All clinical endpoints will be su mmarized with descriptive statis tics without hypothesis testing. 
For continuous variables, the range (minimum, maximum), mean, standard deviation, median, 
first and third quartiles (Q1 and Q3) may be repor ted, while for discrete variables, count and 
percentage will be provided.  
[ADDRESS_257961] Identification 
Subjects that successfully pass the screening tests and wish to participate in the study will be 
assigned a unique identification code (ID ) using the format “XXX-YYY” where: 
 
 XXX = Institution Number, assigned by [CONTACT_214708] = Enrollment Number, assigned by [CONTACT_214709], each subjec t’s initials will be used as an  identifier included on documentation 
submitted to the Sponsor. 
9.2 Central Database 
All study documentation will be collected and compi[INVESTIGATOR_5829] d in a central database .  Appropriate quality 
control measures will be established to ensure acc urate and complete transfer of information from 
the study documentation to the central database. 
 
Protocol Version 6.0  
Page 30 of 45  9.3 Source Documents 
Case Report Forms (CRFs) are not considered acceptable source documents. Source documents 
are original records in which ra w data are first recorded. These may include hospi[INVESTIGATOR_307]/clinic/general 
practitioner records, charts, for example.  Source documents should be kept in a secure, limited 
access area.  Sponsor may request copi[INVESTIGATOR_99606]-identified source  document to adjudicate adverse 
events.   
9.4 Data Collection 
Data will be collected on electronic CRFs supp lied by [CONTACT_16015]. The principal 
investigator [INVESTIGATOR_214676].  The study data are entered into  the eCRFs. Correcti ons made after the 
Investigator’s review and approval mu st be reapproved by [CONTACT_737]. 
A unique study number will be assigned to each s ubject. All information recorded on the CRF 
about the subject will be recorded with the st udy number on it. The main database will contain 
only the study number to identify the subject. The code with subj ect name [CONTACT_214727] a secured location. 
9.5 Data Processing 
Data will be entered / loaded in a validated electronic database using a clinical data management 
system.  Visual and computer error checks will be carried out. The investigator will be queried on 
errors concerning completeness and consistency. An electronic audit trail system will be maintained with the clinical data management sy stem to track all data changes in the database 
once the date has been entered/load ed. Regular backups of the electr onic data will be performed. 
9.[ADDRESS_257962] udy sponsor to ensure that proper monitoring of this investigation 
is conducted.  Appropriately trained monitors, appointed by [CONTACT_4530], will complete any 
monitoring that is  done.  The monitors will ensure th at the investigation is conducted in 
accordance with:  
 The signed Investigator’s Agreement 
 
Protocol Version 6.0  
Page 31 of 45   The Investigational Plan  
 Appropriate laws and regulations  
 Any conditions of approval imposed by [CONTACT_36170]/or  other regulatory 
agencies 
 
The clinical study will be monitored according to  the guidelines summarized below.  The sponsor 
may choose to perform random inspections throughout the study as an element of quality assurance.  Investigators sha ll allow auditing of their clinical investigation procedures. 
A study specific monitoring plan standardizes m onitoring activities acro ss centers to ensure 
human subject protection and verify  data integrity.  The monitors shall receive study specific and 
protocol training prior to conducti ng any monitoring visits.  Study m onitors are selected based on 
their training, qualifications and experience to monitor the progre ss of an investigation.  This 
study monitoring will include a site  qualification, study in itiation, interim, and close out visits.  
All study monitors will be required to follow th e study monitoring plan and monitoring standard 
operating procedures.  
The study monitoring will be done by [CONTACT_214710]: 
Libra Medical Inc 
[ADDRESS_257963] North, Suite 63 Brooklyn Park, MN [ZIP_CODE] 
10.1.2  Monitoring Visit 
The following factors will be ta ken into account when determining the frequency of the 
monitoring visits: subject accrual rate at each center, total number  of subjects enrolled at each 
center, and Clinical Investigation Plan compliance at each center.  It  is anticipated each site will 
be monitored at least once upon th e completion of the 30-day follow- up visits for all enrolled 
subjects at the study site.  Monitors will require di rect access to subjects’ medical records pertinent 
to the study (and study inclusion criteria), st udy management documents, regulatory documents 
and Subject Informed Consent documents, as well as  other potential appli cable records not listed 
here.   
 
Monitors may ensure the clinical investigators ha ve and continue to have  staff and facilities to 
conduct the clinical inve stigation safely and effectively.  Monitors may conduct the following 
monitoring activities throughout the study: 
 
 Verification that the current IRB-approved informed consent was signed and dated by 
[CONTACT_214711]. 
 
Protocol Version 6.0  
Page 32 of 45   Verification of documentation in the subjec t’s record that informed consent was 
signed prior to initia tion of the study procedures and that a copy of the signed and 
dated consent was provided to the subject. 
 Source documentation verification by [CONTACT_214712]. 
 Verification that the investig ation is conducted according to  the Clinical Investigation 
Plan, Instructions for Use and, all malfunc tions/ IFU deficiencies are reported as 
required. 
 Verification that subjects met study enrollment criteria. 
 Verification that study deviati ons are documented and reported. 
 Verification that the procedures for reco rding and reporting adve rse events to the 
sponsor are followed. 
 Ensuring proper error correction. 
 Verification of training docu mentation of all study pers onnel participating in study 
related activities. 
 Reviewing all corresponden ce and regulatory documents, including confirmation of 
IRB-approved Clinical Inves tigation Plan or amendments. 
 Resolution of outstanding issues and completion of assigned tasks will be 
documented by [CONTACT_85231]. 
Each monitoring visit will be documented via a monitoring report and follow-up letter.  The 
follow-up letter shall be sent to the Investigator to document issues identified, corrective actions 
and if applicable preventative actions.  At s ubsequent visits any issues resolved shall be 
documented in this letter to demonstrate resolution. 
10.1.3  Study Closure 
Study closure is defined as a specific date that is determined by [CONTACT_214713]/or 
regulatory requirements have been satisfied per the Clinical Investigation Plan (CIP) and/or by 
[CONTACT_214714].  Study closure vi sits will be conducted at all enrolling clinical 
sites in order to review record retention requi rements with site personne l.  A telephone contact 
[CONTACT_214715] a study closure visit if appropriate (e.g., low subj ect enrollment, recent 
monitoring visit, etc.)  Monitori ng visits will be c onducted by [CONTACT_214716].  
The Monitoring Plan identifies th e frequency of monitoring and training requirements of the 
monitors. 
10.[ADDRESS_257964] be returned  to the Sponsor at the end of 
the study. 
 
Protocol Version 6.0  
Page 33 of 45  The principal investigator [INVESTIGATOR_214677], 
use, return, and disposal of the inves tigational device, which shall include: 
 The date of receipt 
 Identification of each investigatio nal device (serial or lot number) 
 The date or dates of use 
 Subject identification 
 Date of return of unused, expi[INVESTIGATOR_5697], or malfunctioning investigational device, if 
applicable 
 The Investigator must explain in writing the reasons for any discrepancy noted in 
device accountability. 
11 DEFINITION OF ADVERSE EVENT(S) 
For purposes of this study, an a dverse event (AE) is defined as any adverse change (i.e., de novo 
or pre-existing condition) from the subject’s ba seline medical condition(s) occurring during the 
course of the study.  Adverse events (AE) are any untoward medical occurrence, unintended 
disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, 
whether or not related to the investigationa l medical device.  For the purpose of AE 
documentation, the start of the course of the study is defined as any time after the treatment has 
been initiated.  All AE’s will be recorded in the CRF whether considered procedure-related or 
not, and will be classified as described in this section.  
Pre-existing conditions will not be reported as an AE unless there is an adverse change in that 
condition.  Any AE which resolved  and then recurred will be re ported as a separate AE.   
An AE may be volunteered spontaneously by [CONTACT_941] s ubject or discovered as a result of questioning 
or physical examination by [CONTACT_1629] i nvestigator or study staff. 
Elective procedures for a pre-existing condition (t hat has not worsened) are not considered AEs. 
Non-cardiovascular abnormal laboratory values will not be considered AEs unless: 
1) The PI [INVESTIGATOR_214678] e is clinically significant,  
2) The abnormal laboratory valu e required intervention, or  
3) The abnormal laboratory value required subject termination from the trial. 
All adverse events, regardless of relationship to the device, must be recorded, as applicable, on 
the case report forms provided. Adverse events th at occur during this study should be treated by 
[CONTACT_214717], to protect  the life and safety  of the subjects. 
Adverse events shall be assessed and documented at the time of the procedure and at all study 
follow-up visits.  Each investigator shall pr ovide source documentation as requested by [CONTACT_214718]. 
 
Protocol Version 6.0  
Page 34 of 45  11.1 Serious Adverse Events 
An adverse event is considered a Serious Adverse Event (SAE) that: 
a) led to death 
b) led to a serious deterioration in the health of the subject, that either resulted in 
1) a life-threatening illness or injury, or 
2) a permanent impairment of a body structure or a body function, or 
3) in-patient hospi[INVESTIGATOR_214679], or 
4) a medical or surgical intervention to prevent permanent life-threatening 
illness or injury or permanent impairment to body structure or a body function. 
11.[ADDRESS_257965] ed on the appropriate CRF 
form. Determination should be based on asse ssment of temporal relationships, biologic 
plausibility, association (or lack of association) with underlying disease and presence (or absence) 
of a more likely cause. 
11.[ADDRESS_257966] (UADE) is any serious a dverse effect on the health or 
safety of a subject, any life-thr eatening problem or death caused by, or associated with a device, 
if such effect, problem, or deat h was not previously id entified in nature, severity, or degree of 
incidence in the investigational plan (e.g., IC F, Study Protocol, Instructions for Use (IFU), 
publications, etc.), or any other una nticipated serious problem associat ed with a device that relates 
to the rights, safety, or  welfare of subjects. 
If an unanticipated adverse effect associated  with the investigational device occurs, the 
investigator shall notify the Sponsor a nd the IRB/EC as soon as possible.   
The Sponsor will investigate the event and notify the FDA and al l other participating IRBs and 
investigators.  Should the Sponsor determine that  an unanticipated adverse effect presents an 
unreasonable risk to all participa ting subjects, the Sponsor will susp end the clinical investigation 
and notify all participat ing investigators, IRBs/EC, count ry regulatory bodies and FDA.  
11.[ADDRESS_257967] be descri bed by (a) duration (start and 
resolution dates); (b) adjudicated for severity; (c) relationship to the study device; (d) action taken 
to resolve the event; (e) outcome of the event; an d (f) whether or not such event is considered to 
 
Protocol Version 6.[ADDRESS_257968]’s medical  records (such as the subject’s 
laboratory tests and hospi[INVESTIGATOR_17399] l records, Investigator summaries, etc.) to document the adverse event. 
The Investigator will report all serious advers e events, including unanticipated adverse device 
effects, to the IRB according to the IRB require ments. A copy of this IRB communication should 
be sent to the Sponsor. In case of  an unanticipated adve rse device effect occurr ed, the investigator 
must report to the Sponsor within [ADDRESS_257969] provide  the following information: 
 Date of onset 
 Nature 
 Severity 
 Duration / date of resolution 
 Outcome 
 Relationship to investigational device 
 Other relevant information 
11.5.[ADDRESS_257970] determine the severity of the adverse event acc ording to the following 
definitions: 
 
Protocol Version 6.0  
Page 36 of 45   Mild  - The adverse event is noticeable to th e subject, but does not interfere with 
routine activity; the symptoms are easily tolerated and transient in nature. 
 Moderate  – The adverse event interferes with routine activity but responds to 
symptomatic therapy or rest; the sympto ms are poorly tolerated and sustained. 
 Severe  – The adverse event significantly limits the subject’s ability to perform 
routine activities de spi[INVESTIGATOR_4795]. Th e adverse event requires 
medical or surgical treatment or  results in hospi[INVESTIGATOR_059]. 
 Life-Threatening  – The subject is at immediate risk of death. 
11.5.[ADDRESS_257971] provide an assessment of  the adverse event according to the following 
definitions: 
 Definite – The adverse event is clearly related to the investigational device: the 
event has a temporal relationship to the investigational device, follows a known 
pattern of response, or is otherwise logically related to  the investigational device, 
and no alternative cause is present. 
 Probable (Likely) – The adverse event is likely related to the investigational 
device: the event has a temporal relati onship to the investigational device, 
follows a known or suspected pattern of  response, or is otherwise logically 
related to the investigati onal device, but an alterna tive cause may be present. 
 Possible (Unlikely) – The adverse event is unlikely related to the investigational 
device: the event does not follow a clear temporal relationship to the 
investigational device or does not follo w a known pattern of  response, or is 
otherwise likely to be due to the subj ect’s clinical state or other modes of 
therapy. 
 Not Related – The adverse event is clearly not related to the investigational 
device: the event has no te mporal or other relationshi p to the administration of 
the investigational device follows no know n or suspected pattern of response, 
and an alternative cause is present. 
 Unknown – Unable to determine the relationship based on all available 
information. 
11.[ADDRESS_257972] to its identity, quality, 
durability, reliability, safety or performance (i ncludes malfunctions, use errors, and inadequate 
 
Protocol Version 6.0  
Page 37 of 45  labeling).  Sponsor, in cooperation with the CEC, will assess all device deficiencies that could 
have led to a serious adverse device effect for potential re gulatory reporting requirements. 
In the event of a suspected malfunction or device  deficiency, the investigational device(s) shall 
be returned to the manufacture for analysis. Instru ctions for returning the investigational device 
will be provided by [CONTACT_1034]. 
11.[ADDRESS_257973]’s death records, medical records for th e events that led to the subject’s death, and a 
death certificate (if available) a nd an autopsy report (if performed)  should be sent to the sponsor.  
In addition, subject death must be reported to the IRB in acco rdance with IRB requirements. 
12 STUDY ADMINISTRATIV OVERSIGHT 
12.1 Core laboratory 
Independent core laboratories shall be utilized to provide a standardized process and assessment 
of all angiographic and duplex ultrasound studies. The core laboratories will be responsible for 
analyzing the angiograms and ultrasound images acco rding to the study eligibility criteria, the 
study endpoints and this study protoc ol, for providing feedback to the sites and Sponsor regarding 
the quality of the tracings and images and fo r providing a written summary report of all 
angiograms and duplex ultrasound results to the study Sponsor. 
Investigators will enroll subjects  into the study based on inclusion and exclusion criteria. Lesion 
characteristics and measurements will be assessed by [CONTACT_214719]; however, the core laboratory will assess by [CONTACT_214720]. Baseline measurements and 
post-procedure results will be reported by [CONTACT_214721]. 
Angiographic and Ultra Sound Core Laboratory Protocols shall be pr ovided to the investigational 
sites. 
12.2 Clinical Adverse Event Adjudication 
An Independent Adverse Event Adjudicator will be  responsible for the adjudication of any events. 
For this small-scale feas ibility study, one physicia n independent of the study or the sponsor will 
be responsible for the ad judication of any events that may be  considered serious and/or device 
related by [CONTACT_458] [INVESTIGATOR_1238]/or st udy Sponsor. The physician will be familiar with 
PTA procedures who is not an i nvestigator in the trial. The ad judication process will include 
determination of whether the event or device deficiency co nstitutes a SAE or an UADE, or 
contributes to the endpoint, and whether the subj ect should be considered a Procedural Success. 
All available data (including lab reports, films, discharge reports, etc.) will be available to 
adjudicate the events. 
 
Protocol Version 6.0  
Page 38 of 45  12.3 IRB Approval 
The study protocol shall be revi ewed and approved by [CONTACT_8647]’s IRB prior to subject 
enrollment. The Sponsor must review any propos ed changes to the inve stigational informed 
consent prior to implementation.   
Prior to shipment of investiga tional devices, a signed copy of th e IRB approval letter identifying 
the clinical study and investigational site is requi red to be submitted to the Sponsor. Investigators 
are responsible for obtaining and maintaining annual renewal of the study by [CONTACT_11577] (or 
according to renewal schedule imposed by [CONTACT_1201]). Evidence of renewal and continued IRB approval must be provided to the Sponsor accordingly. 
12.[ADDRESS_257974]’s understanding and 
autonomy by [CONTACT_214722]/her own words. 
Once that step is completed, cons ent will be able to be given by [CONTACT_423]’s signing the consent 
form. A copy of the consent form will be given to all consented participants. 
Original signed subject consent forms must be re tained in the study files by [CONTACT_737], and 
available for review by [CONTACT_1052]/ or regulatory agencies, as applicable. 
The informed consent form and any other written in formation provided to subjects will be revised 
whenever important new information becomes avai lable, or if there is an amendment to the 
protocol which necessitates a change to the conten t of subject information and/or to the consent 
form. The Investigator will inform the subject of changes in a timely manner, and will ask the 
subject/patient to confirm his/ her continuation in the study by [CONTACT_2960] a revised consent form. 
Any revised informed consent form and other written information provided to subjects must 
receive IRB, Sponsor, and regulatory agency approval, as applicable. 
 
Protocol Version 6.[ADDRESS_257975] of the study investigation.  The fina l responsibility for main taining such records 
remains with the Investigator.  These records include, but not limited to: 
 All signed agreements; 
 IRB/EC approval letter(s); 
 Signed ICF; 
 Records of AEs, including supporting documents; 
 Records of protocol deviations , including supporting documents 
 Records showing receipt, use and dis position of all invest igational devices, 
including: 
o Date, quantity, model and serial numbers of devices received, 
o Name [CONTACT_52943](s) who received, us ed or disposed of each device, 
o The number of devices returned to the Sponsor and the reason(s) for 
return; 
 All correspondence rela ted to the study; 
 Records of each subject’s case histor y, including study-required CRFs, signed 
ICF, all relevant observations of AEs,  the condition of each subject upon entering 
and during the course of the investigation, relevant medical history, the results of 
all diagnostic testing, etc.; 
 Study personnel visit log; 
 Signature [CONTACT_214728] a nd delegation log; and, 
 Any other records that applicable re gulation requires to be maintained. 
The Investigator will ma intain all essential tria l documents and source documentation that support 
the data collected on the study subjects in co mpliance with FDA’s GCP guidelines. Documents 
must be retained until at least [ADDRESS_257976] 
receive written notification of this custodial change. 
12.6 Reports 
Table 12-1 lists those reports that are the investigator's responsibil ity to deliver to the Sponsor.  
Each study investigator must follow the EC/IRB re porting requirements for their respective site.  
If applicable regulations or EC/IRB requirement s mandate stricter reporting requirements than 
those listed, the stricter re quirements must be followed. 
 
Protocol Version 6.0  
Page 40 of 45  Table 12-1: Reports Required fr om Investigators to Sponsor 
Type of Report Prepared by [CONTACT_976] [INVESTIGATOR_214680], EC/IRB As soon as possible but within 5 working days 
of knowledge 
Death Sponsor, EC/IRB Written reports (e.g., via e-mail) within 48 hours 
SAE  Sponsor 
EC/IRB, if required Within 10 working days of knowledge  
Per IRB requirement 
Device malfunction 
with clinical sequelae Sponsor 
EC/IRB, if required Within 48 hours via written communication.  
Return the device to sponsor within 48 hours. 
Serious protocol 
deviations (e.g., ICF not obtained, to protect the life or physical well-being of a subject in an emergency) Sponsor, 
EC/IRB As soon as possible but within 5 working days 
of knowledge 
Per IRB requirement 
Withdrawal of 
EC/IRB approval Sponsor Within 5 working days of knowledge 
Annual progress 
report Sponsor, EC/IRB Annually 
Interim report Sponsor, EC/IRB Within 14 days of 30-day follow up 
Final report Sponsor, EC/IRB Within 3 months of study completion or 
termination 
Note: Each IRB/EC may require mo re stringent reporting requirements  that those listed in this 
table. 
12.7 Investigator Responsibilities 
 Agree to sign and adhere to the Investigator Agreement. 
 Obtain approval from the IRB including subsequent protocol amendments and 
changes to the Informed Consent form and obtaining annual IRB approval and renewal throughout the duration of the study. 
 Await IRB approval, as well as, any a dditional hospi[INVESTIGATOR_214681] 6.[ADDRESS_257977] to pa rticipate in the study. 
 Complete and provide signed c opi[INVESTIGATOR_214682]. 
 Agree to participate in Investigator meetings as scheduled by [CONTACT_1034]. 
 Be willing to perform and be capable of pe rforming treatment procedures as outlined 
in this protocol. 
 Comply with all required elem ents of this protocol (e.g., perform testing and follow-
up as specified, especially during personnel transitions). 
 Agree to obtain written Informed Consent before any study specific procedures are 
performed in accordance with GCP. 
 Be willing to change hospi[INVESTIGATOR_106148] (as long as subject 
safety and well-being is not compromised). 
 Control any investigational devi ce(s) stored at their site. 
 Be aware of, and comply with, GCP and applicable regulato ry requirements. 
 Permit monitoring and auditi ng by [CONTACT_1034], and insp ection by [CONTACT_214723]. 
 Have available an adequate number of qua lified staff and adequate facilities to 
properly conduct the study. 
 Ensure study personnel are adequately  informed about the protocol, the 
investigational device and study- related duties and functions. 
12.8 Sponsor Responsibilities 
The Sponsors responsibiliti es in the study include: 
 Selecting the Principal Investigator(s), all clinical investigators and study sites, and 
other consultants (e.g., monitors) who participate in the study. 
 Provide study protocol, device, and GCP tr aining to participating study sites, in 
quantities sufficient to suppor t study activities, per agre ements executed with the 
study sites. 
 Select all qualified clinical Investig ators and study sites a nd other consultants (e.g., 
the study monitors) who pa rticipate in the study. 
 Provide financial support to each study site. 
 Follow/promote all regulatory standards pe r appropriate regulati ons for study sites, 
core laboratories, and other participants, and ensure compliance by [CONTACT_214724]. 
 Ensure completion of site monitoring of clin ical data at each clinical study site.  
 
Protocol Version 6.0  
Page 42 of 45   Retain ownership of all clin ical data generate d in this study, and control the use of 
the data for appropriate purposes only.   
 Review and approve publication of study results in the literature 
12.9 Protocol Deviations / Violati ons and Medical Emergencies 
A protocol deviation or vi olation is a failure to comply with th e requirements of the clinical study 
as specified in the protocol. Examples of protoc ol deviations include la te visits, missed visits, 
required follow-up testing not completed. An ex ample of a major protoc ol violation includes 
enrollment of a study subject who fails to meet inclusion/exclusio n criteria as specified in the 
protocol. Each investigator shall conduct this cl inical study in accordance with the study protocol 
and any conditions required  by [CONTACT_3488]. 
Deviations/violations from clinical protocol requirements will be reviewed and evaluated on an 
ongoing basis and, as necessary, appropriate correc tive actions put into place.  See Table 12-1: 
Reports Required from Investigators to Sponsor for reporting timelines for emergency deviation. 
12.[ADDRESS_257978] be provided 
to Cardio Flow, Inc.: 
 Signed protocol/pro tocol amendments 
 Signed and dated Investigator Agreement(s) 
 A copy of the written IRB approval of the protocol 
 A copy of the written IRB approval of the Informed Consent Form 
 Signed and dated Curriculum V itae of the Investigator(s) 
 Copy of the Investigator(s)’ current medical license(s), or equivalent 
 Signed and dated Non-disclosure  Agreement(s), if required 
 Signed and dated Certification/ Financial Disclosure Form(s) 
12.11  Criteria for Terminating Study 
The Sponsor reserves the right to terminate the study but intends  only to exercise this right for 
valid scientific or administra tive reasons and reasons related to protection of subjects. 
Investigators and associated IRB will be notif ied in writing in the event of termination. 
Possible reasons for study termination include: 
 The discovery of an unexpected, significan t, or unacceptable risk to the subjects 
enrolled in the study. 
 A decision on the part of the Sponsor to suspend or discontinue development of the 
device. 
 
Protocol Version 6.[ADDRESS_257979] 
or ACC and then submitted to a peer reviewed medical journal. 
13 REVISION HISTORY 
Date Description 
May 1, 2017 Version 1.0.  Initial Release 
May 31, 2017 Version 2.0. Clarify that H4001 device will be 
used in this trial. 
June 28, 2017 Version 3.0. Clarify how target lesions will be 
numbered. 
July 7, 2017 Version 4.0. Incorporate PI’s comments 
October 4, 2017 Version 5.0. Incorporate FDA’s comments from 
IDE G170219 disapproval letter dated September 29, 2017 
November 18, 2017 Version 6.0 Incorporates FDA’s email request to 
insert warnings about  the possibility of 
vasospasm and potential tissue damage and preventive measures. Added Exclusion of subjects Lacking capacity  to provide consent.  
 
  
 
Protocol Version 6.0  
Page 44 of 45  14 BIBLIOGRAPHY 
1. Mohler ER. Peripheral arterial disease: identification and implications. Arch. Intern. Med 2003;163: 2306-
2314. 
2. Hirsch AT, Haskal ZJ, Hertzet NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA guidelines for the 
management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A Collaborative Report from the American Associa tion for Vascular Surgery/Society for Vascular 
Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, 
Society for Vascular Medicine and Biology, and th e American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the 
Management of Patients With Peripheral Arterial Disease). Accessed Apr 27, 2007. Available at URL 
address: http://www.acc.org/clin ical/guidelines/pad/index.pdf.  
3. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epi[INVESTIGATOR_623], pathophysiology, 
and management. JAMA 2002;287(9):2570-2581. 
4. Bashir R, Cooper CJ. Evaluation and treatment of peripheral arterial disease. Curr Opin 
Cardiol. 2003;18(6):436-443 
5. Brunton S, Belotserkovaya Y, Marinovich A, Mirohnik M, Monahemi P. A practical look at the long-
term management of intermittent claudication. Resident & Staff Physician. 2003; 49(9):10-15. 
6. Criqui MH. Peripheral arterial disease—epi[INVESTIGATOR_214683]. Vasc Med. 2001; 6(suppl 1):3-7. 
7. Comerota AJ. Endovascular and surgical revascularization for patients with intermittent claudication. 
Am J Cardiol. 2001;87(suppl):34D-43D. 
8. Dermott MM, Greenland P, Liu K, Guralnik JM, Cr iqui MH, Dolan NC, Chan C, Celic L, Pearce WH, 
Schneider JR, Sharma L, Clark E, Gibson D, Martin GJ. Leg symptoms in peripheral arterial disease: 
associated clinical characteristics and functio nal impairment. JAMA. 2001;286(13):1599-1606. 
9. Criqui MH, Fronek A, Barrett-Connor E et al. The prevalence of peripheral arterial disease in a 
defined population. Circulation 1985a; 71: 510-15. 
10. Murabito JM, D'Agostino RB, Silbershatz H, et al . Intermittent claudication. A risk profile from 
The Framingham Heart Study. Circulation 1997;96:44-9. 
11. Bainton D, Sweetnam P, Baker I, et al. Peripheral  vascular disease: cons equence for survival and 
association with risk factors in th e Speedwell prospective heart disease study. Br Heart J 1994; 72:128-32. 
12. Stewart KJ, Hiatt WR, Regensteiner JG, et al. Ex ercise training for claudication. N Engl J Med 
2002;347:1941- 51. 
13. McDermott MM, Greenland P, Liu K, Guralnik JM, Criq ui MH, Chan C, Martin GJ, Schneider J, Pearce 
WH, Taylor LM, Clark E. The ankle-brachial index is associated with leg function and physical activity: the 
walking and leg circulation study. Ann Intern Med 2002;136(12):873-83. 
14. Hirsch AT, Ekers MA. A comprehensive vascular medical therapeutic approach to pe ripheral arterial disease: 
the foundation of effective vascular rehabilitation. In: Fahey VA, ed. Vascular Nursing. 3rd ed. Philadelphia, 
Pa: WB Saunders; 1999:188-211.  
15. Jamsen T, Manninen H, Tulla H, et al. The fina l outcome of primary infrainguinal percutaneous 
transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia. J Vasc Interv 
Radiol 2002;13:455- 63. 
16. Vroegindeweij D, Tielbeek AV, Buth J, et al. Directional atherectomy versus balloon angioplasty in 
segmental femoropopliteal artery disease: two-year follow-up with color-flow duplex scanning. J Vasc Surg 
1995;21:255- 68; discussion 268-9.  
17. 
Laird Jr J. R., Reiser C., Biamino G., Zeller T.  Limb Salvage for Chronic Arterial Occlusive 
Disease: Indications And Management. J Cardiovasc Surg (Torino) 2004 :45(3), 239 – 248. 
18. Isner JM, Pi[INVESTIGATOR_214684] A, Schainfeld R, et al. Clinical evidence of angiogen esis after arterial gene transfer 
 
Protocol Version 6.0  
Page 45 of 45  of phVEGF165 in patient with ischaemic limb. Lancet 1996;348:370-4.  
19. Ingle H, Nasim A, Bolia A, et al. Subintimal angioplasty of isolated infragenicular vessels in lower limb 
ischemia: long-term results. J Endovasc Ther 2002;9:411-6. Erratum in: J Endovasc Ther 2002;9:A-6. 
 
20. Jacobs D, Motaganahalli R, Cox D, Wittgen C, Pete rson G. True lumen re-entry devices facilitate 
subintimal angioplasty and stenting of total chronic occlusions: Initial report.  Journal of Vascular 
21. Surgery, 2006:43(6), 1291-1296. 
22. Pi[INVESTIGATOR_214685], Pearce WH, Jones DN, Whitehill T, Bell R, Patt A, Rutherford RB. Aortobifemoral by[CONTACT_6476]: 
the operation of choice for unilateral iliac occlusion? J Vasc Surg. 1989 Jul;10(1):105-6. 
 
23. Powell RJ, Fillinger M, Walsh DB, et al. Predicti ng outcome of angioplasty and selective stenting 
of multisegment iliac artery occlusive disease. J Vasc Surg 2000;32:564-9.  
 